Brodalumab approval recommended, despite possible suicide signal

A Food and Drug Administration advisory committee has unanimously supported approval of the monoclonal antibody brodalumab for the treatment of moderate to severe plaque psoriasis, with the majority recommending risk management options beyond labeling to address concerns about the six completed...
Source: Skin and Allergy News - Category: Dermatology Source Type: news